<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01424033</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00049434</org_study_id>
    <nct_id>NCT01424033</nct_id>
  </id_info>
  <brief_title>A Clinical Trial for CTD-ILD Treatment</brief_title>
  <official_title>Clinical Trial of Oral Medication for CTD-ILD Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The first objective of this protocol is to assess the tolerability and safety of
      N-acetylcysteine (NAC) in patients with connective tissue disease related interstitial lung
      disease (CTD-ILD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will assess tolerability and safety at scheduled intervals via standard of
      care physical exam findings, monitoring complete blood count, serum chemistry, and pulmonary
      function tests, along with patient reports of medication intolerance and change in symptoms
      of dyspnea.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Departure of study team
  </why_stopped>
  <start_date>December 2011</start_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary Function Tests</measure>
    <time_frame>Every 3 months</time_frame>
    <description>Not recorded. Study terminated due to departure of PI.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Interstitial Lung Disease</condition>
  <condition>Connective Tissue Disease</condition>
  <arm_group>
    <arm_group_label>N-Acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is an open label trial, all patient will be entered into one treatment arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-Acetylcysteine</intervention_name>
    <description>600mg by mouth, three times daily for 12 months</description>
    <arm_group_label>N-Acetylcysteine</arm_group_label>
    <other_name>NAC</other_name>
    <other_name>acetylcysteine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          1. Subject gives voluntary written informed consent to participate in the study.

          2. Subject has been diagnosed with a connective tissue disease and associated
             interstitial lung disease confirmed by computed tomography of the lungs along with
             symptoms of cough and/or shortness of breath.

          3. Males and females age greater than 18 years at time of screening.

          4. Females of childbearing potential must be willing to use a reliable form of medically
             acceptable contraception and have a negative pregnancy test confirmed at baseline
             before starting NAC as per standard of care. Women who are surgically sterile or have
             been post-menopausal for at least two years are not considered to be of child-bearing
             potential.

        Exclusion:

          1. History of severe chronic kidney disease defined as a glomerular filtration rate of
             less than 30.

          2. Hemoglobin concentration less than 70% of the lower limit of the normal range at time
             of screening.

          3. Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2011</study_first_submitted>
  <study_first_submitted_qc>August 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2011</study_first_posted>
  <results_first_submitted>January 14, 2016</results_first_submitted>
  <results_first_submitted_qc>January 14, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 12, 2016</results_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Kristine Phillips</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Interstitial lung disease</keyword>
  <keyword>Connective tissue disease</keyword>
  <keyword>Scleroderma</keyword>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>Sjogren's syndrome</keyword>
  <keyword>Mixed connective tissue disease</keyword>
  <keyword>Dermatomyositis</keyword>
  <keyword>Polymyositis</keyword>
  <keyword>Systemic lupus erythematosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Connective Tissue Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>5 subjects consented but did not participate in study due to departure of PI from institution.</recruitment_details>
      <pre_assignment_details>5 subjects consented to participate due to the PI departed the institution. Numbers in patient flow were updated to reflect this.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>N-Acetylcysteine</title>
          <description>This is an open label trial, all patient will be entered into one treatment arm.
N-Acetylcysteine: 600mg by mouth, three times daily for 12 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>N-Acetylcysteine</title>
          <description>This is an open label trial, all patient will be entered into one treatment arm.
N-Acetylcysteine: 600mg by mouth, three times daily for 12 months</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pulmonary Function Tests</title>
        <description>Not recorded. Study terminated due to departure of PI.</description>
        <time_frame>Every 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-Acetylcysteine</title>
            <description>This is an open label trial, all patient will be entered into one treatment arm.
N-Acetylcysteine: 600mg by mouth, three times daily for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Function Tests</title>
          <description>Not recorded. Study terminated due to departure of PI.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>N-Acetylcysteine</title>
          <description>This is an open label trial, all patient will be entered into one treatment arm.
N-Acetylcysteine: 600mg by mouth, three times daily for 12 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Patient with rapid decline in her health due to new onset scleroderma, pulmonary fibrosis, and cardiac arrhythmia.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hospitalization, tachycardia</sub_title>
                <description>Patient with known history of cardiac disease and tachycardia was hospitalized with tachycardia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cancer recurrence</sub_title>
                <description>Patient with a known history of cancer had a recurrence of breast cancer</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Five subjects were consented. Study was terminated prior to conclusion due to departure of PI.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jan Stevens</name_or_title>
      <organization>University of Michigan</organization>
      <phone>7349365566</phone>
      <email>janstev@med.umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

